OTCMKTS:LYRA

Lyra Therapeutics (LYRA) Stock Price, News & Analysis

Lyra Therapeutics logo
$0.03 -0.16 (-84.21%)
As of 11/17/2026 12:10 PM Eastern

About Lyra Therapeutics Stock (OTCMKTS:LYRA)

Advanced

Key Stats

Today's Range
$0.03
▼
$0.03
50-Day Range
$0.03
▼
$0.20
52-Week Range
$0.00
▼
$4.59
Volume
266 shs
Average Volume
1,040 shs
Market Capitalization
$53.10 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Lyra Therapeutics is a U.S.-based biotechnology company that has focused on developing localized treatments for chronic rhinosinusitis, a long-lasting inflammatory condition affecting the nose and sinuses.

The company’s investigational candidates, LYR-210 and LYR-220, are bioabsorbable implants designed to deliver mometasone furoate, a corticosteroid, directly to nasal and sinus tissues over an extended period. The treatments were developed for administration by a health care provider, with the goal of providing sustained therapy without relying solely on daily medication.

Lyra has evaluated these candidates in clinical studies. They are investigational products and are not approved treatments. The company’s work has centered on the U.S. market and on developing alternatives for people whose chronic sinus symptoms are not adequately managed with existing medical care.

AI Generated. May Contain Errors.

Lyra Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
3rd Percentile Overall Score

LYRA MarketRank™: 
0.142037876765 of 5 stars

Lyra Therapeutics scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lyra Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Lyra Therapeutics has received no research coverage in the past 90 days.

  • Read more about Lyra Therapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lyra Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lyra Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Lyra Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.28% of the float of Lyra Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lyra Therapeutics has a short interest ratio ("days to cover") of 1.82, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lyra Therapeutics has recently decreased by 0.15%, indicating that investor sentiment is improving.
  • Dividend Yield

    Lyra Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Lyra Therapeutics does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 1 news article for Lyra Therapeutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Lyra Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    3.25% of the stock of Lyra Therapeutics is held by insiders.

  • Percentage Held by Institutions

    95.62% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lyra Therapeutics' insider trading history.
Receive LYRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LYRA Stock News Headlines

Lyra Therapeutics (LYRA) Set to Release Earnings on Tuesday
Lyra Therapeutics Inc.
My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
See More Headlines

LYRA Stock Analysis - Frequently Asked Questions

Lyra Therapeutics' stock was trading at $3.08 at the beginning of the year. Since then, LYRA stock has decreased by 99.0% and is now trading at $0.03.

Lyra Therapeutics, Inc. (OTCMKTS:LYRA) announced its quarterly earnings results on Wednesday, November, 12th. The company reported ($3.38) earnings per share for the quarter, beating analysts' consensus estimates of ($5.98) by $2.60. The company earned $25 thousand during the quarter, compared to the consensus estimate of $206 thousand.

Lyra Therapeutics's stock reverse split on the morning of Wednesday, May 28th 2025.A 1-50 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lyra Therapeutics investors own include Ceragon Networks (CRNT), Editas Medicine (EDIT), Palantir Technologies (PLTR), Nokia (NOK), Heron Therapeutics (HRTX), Aktis Oncology (AKTS) and Advanced Micro Devices (AMD).

Company Calendar

Today
11/18/2026
Next Earnings (Estimated)
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:LYRA
Previous Symbol
NASDAQ:LYRA
CIK
1327273
Fax
N/A
Employees
27
Year Founded
2005

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$400 thousand
Price / Sales
0.13
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($6.04) per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
1,770,000
Free Float
1,717,000
Market Cap
$53.10 thousand
Optionable
No Data
Beta
-0.29

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (OTCMKTS:LYRA) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners